Oppenheimer maintains Amrize at Outperform, lowers price target to $52 from $55

Oppenheimer kept its Outperform rating on Amrize but reduced its price target to $52 from $55, citing a 5.5% decrease. The new target suggests a 25.7% upside from the Oct 30 close of $41.38. Recent analyst price targets for Amrize range from $39 to $48.

Original reporting
Published Nov 2, 2026, 4:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 2, 2026, 4:53 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Oppenheimer maintains Amrize at Outperform, lowers price target to $52 from $55 — source image
Decision brief

The 30-second read

$AMRZNeutralLow
01

Why it matters

For traders, the actionable element is the revised target level and implied upside, which can affect short-term sentiment and expectations even without new company-specific news.

02

Market read

A single analyst price-target cut with rating unchanged, likely to cause only modest sentiment impact absent new fundamentals.

03

What to watch

Price-target ranges across recent notes ($39 to $48) suggest the stock is still within a contested valuation band; positioning may matter more than the single target change.

Relevance 4/10Novelty 3/10Timing: today’s analyst-note update, after-hours/late session read-through

Background

The article summarizes an Oppenheimer analyst action on Amrize, focusing on a maintained rating and a reduced price target.

Company-level read

Ticker impact

$AMRZNeutralMedium confidence
Context

Oppenheimer maintained Amrize at Outperform and cut its price target to $52 from $55, implying a revised valuation outlook for AMRZ.

Expected impact

Likely mild downward pressure or reduced upside as the market digests the target cut, partially offset by the unchanged Outperform stance.

Evidence & confidence

This is a sell-side price-target change without new company fundamentals in the article; retained Outperform suggests limited bearish intent, but the target reduction can still influence sentiment and positioning.

Market effects

Minimal, as this is a single-name analyst target adjustment with no sector-wide catalyst described.

None indicated.

None indicated.

Counterpoint

The target cut may reflect valuation conservatism rather than deteriorating fundamentals, so the market may largely ignore it if other catalysts dominate.

Key entities

  • Amrize

    Subject of the analyst action, with Oppenheimer maintaining Outperform and lowering the price target to $52.

  • Oppenheimer

    Brokerage issuing the maintained rating and lowered price target.

Related articles

$AMRZHigh

Jefferies downgrades Amrize stock rating on margin concerns

Jefferies downgraded Amrize (NYSE:AMRZ) to Underperform, cutting its price target to $35.20 from $42.80. Analyst Glynis Johnson cited margin concerns due to rising costs and tough comparisons in 2027. The stock is down 23% year-to-date. Jefferies forecasts continued cost pressures will impact margins. Amrize reported Q3 2026 earnings beating profit estimates but missing revenue targets.

$BETAMed

5 Stocks Analysts Just Downgraded

Wall Street analysts downgraded five stocks: BETA Technologies (BETA), TransUnion (TRU), Molson Coors (TAP), Amrize (AMRZ), and another. Downgrades cited delivery delays, slower growth, soft demand, and cost pressures. BETA's Q3 revenue doubled, but deliveries were delayed. TransUnion's revenue rose 12.2%, but margins slipped. Molson Coors saw net sales fall 1.6% and lowered earnings guidance. Amrize adjusted EBITDA and revenue forecasts due to cost inflation.

Med

Amrize Q3 2026 slides: pricing drives margins amid volume headwinds

Amrize reported Q3 2026 revenues of $3.77B, up 2.2% YoY, with net income rising 3.3% to $558M. Pricing initiatives and acquisitions offset volume declines due to weather. Building Materials segment grew 1.8%, while Building Envelope faced challenges. Guidance updated to $12.2B-$12.4B in revenue and $2.95B-$3.05B in adjusted EBITDA for 2026.

$AMRZMed

DA Davidson raises Amrize stock price target to $43 on mixed Q3

DA Davidson raised its price target for Amrize (NYSE:AMRZ) to $43, citing mixed Q3 results with strong Building Materials offset by Building Envelope pressure. The stock is up 5.5% weekly but down 22% in six months. Amrize guided below consensus but beat EPS estimates by 2.06% while missing revenue by 0.95%. DA Davidson maintains a Neutral rating, awaiting more execution visibility.

$AMRZHighAI 9/10

What Amrize (AMRZ) Said on Its Q3 Earnings Call

Amrize (AMRZ) reported Q3 revenue growth of 1.8% to $2.8B in Building Materials and 3.6% to $929M in Building Envelope. Adjusted EBITDA rose 2.7% in Building Materials but fell 14.6% in Building Envelope due to higher costs. The company expects price-over-cost positivity in Building Envelope by 2027. Amrize reaffirmed its 2026 outlook, targeting $12.2B-$12.4B in revenue and $2.95B-$3.05B in EBITDA. It returned $1.1B to shareholders through dividends and repurchases.

$AMRZMed

Amrize Ltd (AMRZ) Q3 2026 Earnings Call Highlights: Pricing Power Drives Growth

Amrize Ltd (AMRZ) reported Q3 2026 earnings, with revenue and EBITDA guidance updated to $12.2-$12.4B and $2.95-$3.05B. Cement volumes fell 4.2% YoY due to weather, while building envelope EBITDA declined 14.6% from inflation. Price-cost positivity in building envelope delayed to 2027. CEO Jan Jenisch expects 2027 growth but cites inflation and interest rate uncertainties. Free cash flow conversion below 50% target due to higher CapEx.